Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 22 (1), 2

The Emerging Role of Local Therapy in Metastatic Prostate Cancer

Affiliations
Review

The Emerging Role of Local Therapy in Metastatic Prostate Cancer

Nora Sundahl et al. Curr Oncol Rep.

Abstract

Purpose of review: This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer.

Recent findings: The phase 3 STAMPEDE trial showed that prostate radiotherapy confers a survival benefit for newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer (HSPC). No survival benefit was noted for those with high volume disease. A subsequent meta-analysis combining the data of the STAMPEDE trial with that of the HORRAD trial corroborated these findings. The phase 2 randomized STOMP trial investigated local treatment of metastases in patients with oligometastatic HSPC, and showed an improvement in hormone therapy-free survival. Local prostate radiotherapy should be offered to patients with newly diagnosed low volume metastatic HSPC. Early clinical evidence suggests that local treatment to metastatic disease might be beneficial for patients with oligometastatic HSPC, but larger trials are awaited.

Keywords: Hormone therapy–relapsed prostate cancer; Hormone-sensitive prostate cancer; Prostate cancer; Radiotherapy.

Similar articles

See all similar articles

References

    1. Lancet Oncol. 2009 Jul;10(7):718-26 - PubMed

References

    1. Eur Urol. 2015 May;67(5):852-63 - PubMed

References

    1. Cancer Discov. 2018 Apr;8(4):444-457 - PubMed

References

    1. Cancer Cell. 2009 Jan 6;15(1):35-44 - PubMed

References

    1. N Engl J Med. 2016 Oct 13;375(15):1415-1424 - PubMed

References

    1. Int J Cancer. 2018 Sep 1;143(5):1236-1248 - PubMed

References

    1. Eur Urol. 2019 Jul;76(1):115-124 - PubMed

References

    1. J Clin Oncol. 2016 Aug 20;34(24):2835-42 - PubMed

References

    1. Eur Urol. 2019 Mar;75(3):410-418 - PubMed

References

    1. BMJ. 2010 Mar 30;340:c117 - PubMed

References

    1. Cell. 2013 Nov 7;155(4):750-64 - PubMed

References

    1. J Clin Oncol. 2018 Feb 10;36(5):446-453 - PubMed

References

    1. Eur Urol. 2014 Jun;65(6):1058-66 - PubMed

References

    1. Nature. 2015 Apr 16;520(7547):353-357 - PubMed

References

    1. Mol Cancer. 2017 Dec 02;16(1):176 - PubMed

References

    1. Eur Urol. 2015 Jan;67(1):3-6 - PubMed

References

    1. Nature. 2005 Dec 8;438(7069):820-7 - PubMed

References

    1. Nat Commun. 2017 Jun 09;8:15618 - PubMed

References

    1. Nat Rev Clin Oncol. 2011 Jun 07;8(8):504-6 - PubMed

References

    1. N Engl J Med. 2015 Aug 20;373(8):737-46 - PubMed

References

    1. Lancet Oncol. 2014 Jun;15(7):700-12 - PubMed

References

    1. Lancet. 2019 May 18;393(10185):2051-2058 - PubMed

References

    1. BMC Cancer. 2014 Sep 15;14:671 - PubMed

References

    1. Lancet Oncol. 2016 Dec;17(12):1672-1682 - PubMed

References

    1. Nature. 2013 Aug 22;500(7463):415-21 - PubMed

References

    1. Clin Oncol (R Coll Radiol). 2019 Dec;31(12):824-833 - PubMed

References

    1. CA Cancer J Clin. 2017 Jan;67(1):65-85 - PubMed

References

    1. Eur Urol. 2019 May;75(5):707-711 - PubMed

References

    1. Nat Cell Biol. 2006 Dec;8(12):1369-75 - PubMed

References

    1. N Engl J Med. 2015 Oct 29;373(18):1697-708 - PubMed

References

    1. Nat Commun. 2018 Mar 21;9(1):1176 - PubMed

References

    1. Sci Transl Med. 2015 Nov 4;7(312):312re10 - PubMed

References

    1. Eur Urol. 2014 Sep;66(3):602-3 - PubMed

References

    1. Eur Urol. 2019 Apr;75(4):667-675 - PubMed

References

    1. Nat Rev Cancer. 2009 Apr;9(4):285-93 - PubMed

References

    1. J Clin Oncol. 2019 Jun 20;37(18):1558-1565 - PubMed

References

    1. Cell. 2008 Apr 4;133(1):66-77 - PubMed

LinkOut - more resources

Feedback